Improving target volume delineation for 3D image-based dosimetry in PRRT

Peptide receptor radionuclide therapy (PRRT) using radiolabelled somatostatin analogues is currently the most effective molecular radiotherapy (MRT) treatment for patients who suffer from neuroendocrine tumours (NET) with metastasised disease. In PRRT the treatment is systemic and the most frequent treatment protocol is to administer 7.4GBq of Lu-177 up to four times with a six to 10-week interval between each administration. The cumulative absorbed dose that can be administered to the tumour is limited by the unavoidable irradiation of the organs at risk (OAR), such as kidneys and bone marrow.

The content on this page is provided by the individuals concerned and does not represent the views or opinions of RAD Magazine.

Stay up to date with
RAD Magazine

Sign up for our newsletter.

We care about your data. Read our privacy policy.